Recall Register

Device recall: NxStage PureFlow B Solution-RFP-400, Premixed Dialysate for Hemodialysis. NxStage PureFlow B Solution is indicated for…

Class II FDA enforcement event 81445. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

PureFlow B Solution smaller chamber of the two chamber bag can burst electrolyte fluid and cause injury if it comes in contact with the eyes or skin

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

NxStage Medical, Inc. started this device recall on 17 Oct 2018. The firm address in the FDA record is in Lawrence, MA. FDA put the recall in Class II. FDA event 81445 has 8 product records. The first FDA enforcement report date is 5 Dec 2018. The record gives the status Terminated, with the termination date 26 Aug 2020.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

US Nationwide Distribution.

Recalling firm

NxStage Medical, Inc., Lawrence, MA.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

8 product records in the event.

FDA event 81445: product records
Recall numberProductQuantityClassStatusReport date
Z-0500-2019NxStage PureFlow B Solution-RFP-400, Premixed Dialysate for Hemodialysis. NxStage PureFlow B Solution is indicated for use with renal replacement therapy systems that utilize sterile premixed dialysate during hemodialysis.59100Class IITerminated5 Dec 2018
Z-0501-2019NxStage PureFlow B Solution-RFP-401, Premixed Dialysate for Hemodialysis NxStage PureFlow B Solution is indicated for use with renal replacement therapy systems that utilize sterile premixed dialysate during hemodialysis.186476Class IITerminated5 Dec 2018
Z-0502-2019NxStage PureFlow B Solution-RFP-402, Premixed Dialysate for Hemodialysis NxStage PureFlow B Solution is indicated for use with renal replacement therapy systems that utilize sterile premixed dialysate during hemodialysis.21071Class IITerminated5 Dec 2018
Z-0503-2019NxStage PureFlow B Solution-RFP-403, Premixed Dialysate for Hemodialysis NxStage PureFlow B Solution is indicated for use with renal replacement therapy systems that utilize sterile premixed dialysate during hemodialysis.2189Class IITerminated5 Dec 2018
Z-0504-2019NxStage PureFlow B Solution-RFP-404, Premixed Dialysate for Hemodialysis NxStage PureFlow B Solution is indicated for use with renal replacement therapy systems that utilize sterile premixed dialysate during hemodialysis.114777Class IITerminated5 Dec 2018
Z-0505-2019NxStage PureFlow B Solution-RFP-406, Premixed Dialysate for Hemodialysis NxStage PureFlow B Solution is indicated for use with renal replacement therapy systems that utilize sterile premixed dialysate during hemodialysis.16585Class IITerminated5 Dec 2018
Z-0506-2019NxStage PureFlow B Solution-RFP-RFP-454, Premixed Dialysate for Hemodialysis NxStage PureFlow B Solution is indicated for use with renal replacement therapy systems that utilize sterile premixed dialysate during hemodialysis.7275Class IITerminated5 Dec 2018
Z-0507-2019NxStage PureFlow B Solution-RFP-RFP-456, Premixed Dialysate for Hemodialysis NxStage PureFlow B Solution is indicated for use with renal replacement therapy systems that utilize sterile premixed dialysate during hemodialysis.15880Class IITerminated5 Dec 2018

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Device events that started in 2018
1,074
Share of these events in Class II
92%
Product records in this event
8Median of the firm: 1
Events of the firm on the register
13

Other events of the firm

Official channels

Cite this page

Recall Register. FDA enforcement event 81445. https://recallregister.com/fda/ii/81445/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA device enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: US Nationwide Distribution.
What quantity of product is in FDA event 81445?
The event has 8 product records. The first record gives this quantity: 59100
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many device recalls of 2018 have the same class?
92% of the 1,074 device events that started in 2018 are in Class II.